2021 American Transplant Congress
The Importance of Persistent and Recurrent T Cell Mediated Rejection in Tacrolimus Treated Renal Transplant Recipients
*Purpose: Optimal follow-up after treatment for T-cell mediated rejection (TCMR) is not well-established. We sought to identify the prevalence and clinical associations of repeated TCMR…2021 American Transplant Congress
Baseline Levels of Dd-cf Dna After Pancreas Transplantation: Using Dd-cfdna as an Indicator for Pancreas Rejection and Biopsy Avoidance
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) testing, which has been previously validated for monitoring kidney transplant (KTx) rejection, may provide an alternative to pancreas biopsy that…2021 American Transplant Congress
The Impact of Early Narcotic Administration on Intestinal Transplantation Survival at an Urban Medical Center
*Purpose: The impact of early narcotic administration on intestinal transplant patients is not well understood, with current practice suggesting the avoidance of narcotics among transplant…2021 American Transplant Congress
Influence of Induction Therapy and Antiretroviral Regimen on Outcomes in HIV Positive Renal Transplant Recipients
*Purpose: Transplantation of HIV+ individuals has become more common over the past decade with increasing data supporting good outcomes. Questions remain regarding the impact of…2021 American Transplant Congress
Reassessing TCMR in Kidney Transplant Indication Biopsies: Emerging Evidence for Partial Exhaustion in Late TCMR
1Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, 2., ., AB, Canada
*Purpose: We rederived the MMDx rejection archetypes in an expanded set of 1679 kidney transplant biopsies to add power and potentially define heterogeneity in TCMR.…2021 American Transplant Congress
Single-Cell RNA-seq Identifies Intra-Graft Population Heterogeneity in Acute Heart Allograft Rejection in the Mouse
*Purpose: Transplant rejection remains a major barrier to graft survival and involves a diversity of cell types. But the heterogeneity in a given cell type…2021 American Transplant Congress
Athena – Effect of Primary Immunosuppression on Development of De Novo Donor Specific Antibodies within First Year After Kidney Transplantation
1ATHENA, Study Group, Germany, 2Novartis Pharma GmbH, Nuremberg, Germany
*Purpose: The ATHENA trial [NCT01843348] investigated safety and efficacy of everolimus combined with cyclosporine A [EVR/CsA] or tacrolimus [EVR/TAC] vs. tacrolimus plus mycophenolic acid [MPA/TAC]…2021 American Transplant Congress
Single Center Experience Comparing Two Clinically Available Donor Derived Cell Free DNA Tests
*Purpose: Donor derived cell-free DNA (dd cf-DNA), this new technology allows for non-invasive monitoring of graft function. Two most commonly used assays are Prospera (Natera®,…2021 American Transplant Congress
Torque Teno Virus Load Predicts Allograft Rejection but Not Viral Infection After Kidney Transplantation; A Cohort Joint Modelling Study
*Purpose: The main challenge of immunosuppressive therapy after solid organ transplantation is to find the optimal dose regimen, and prevent allograft rejection as well as…2021 American Transplant Congress
Desensitization with Plasmapheresis and IV Immunoglobulin is Safe and Effective in Pra Positive Kidney Transplant Recipient Candidates in Covid-19 Pandemic Period
*Purpose: High panel reactive antibody (PRA) levels may limit living-donor kidney transplantation (LDKT) according to increased risk of antibody mediated rejection. Desensitization may provide better…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 172
- Next Page »